QUOTE AND NEWS
SeekingAlpha  Mar 10  Comment 
By Long Term Bio: (Editor’s Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.) One biotech name that investors...
DailyFinance  Dec 23  Comment 
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna®, a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the closing of the previously...
DailyFinance  Dec 18  Comment 
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biotechnology company developing Tcelna®, a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the pricing of an underwritten public...
DailyFinance  Dec 17  Comment 
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today announced that it intends to offer shares of its common stock in an underwritten secondary public...
DailyFinance  Dec 16  Comment 
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna®, a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), is pleased to announce the enrollment of the 126th...
Benzinga  Sep 25  Comment 
Opexa Therapeutics, Inc. (NASDAQ: OPXA) today announced the conversion of the Company's outstanding 12% convertible secured promissory notes into shares of common stock. Notes in the aggregate principal amount of $3.185...
StreetInsider.com  Aug 14  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Opexa+Therapeutics%2C+Inc.+%28OPXA%29+Narrows+Q2+Loss/8599615.html for the full story.
StreetInsider.com  Aug 8  Comment 
Opexa Therapeutics, Inc. (Nasdaq: OPXA) 49% LOWER; announced the pricing of an underwritten public offering of 12 million shares of its common stock at a price to the public of $1.50 per share. The gross proceeds to Opexa from this offering are...
Benzinga  Aug 8  Comment 
Opexa Therapeutics, Inc. (NASDAQ: OPXA) today announced the pricing of an underwritten public offering of 12 million shares of its common stock at a price to the public of $1.50 per share. The gross proceeds to Opexa from this...
StreetInsider.com  May 14  Comment 
PDI, Inc. (Nasdaq: PDII) 30.8% HIGHER; reported Q1 EPS of $0.14, $0.25 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $42.9 million versus the consensus estimate of $38.02 million. Opexa Therapeutics, Inc....





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki